374 related articles for article (PubMed ID: 33811979)
1. Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone.
Hanudel MR; Wong S; Jung G; Qiao B; Gabayan V; Zuk A; Ganz T
Kidney Int; 2021 Jul; 100(1):79-89. PubMed ID: 33811979
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease.
Koury MJ; Agarwal R; Chertow GM; Eckardt KU; Fishbane S; Ganz T; Haase VH; Hanudel MR; Parfrey PS; Pergola PE; Roy-Chaudhury P; Tumlin JA; Anders R; Farag YMK; Luo W; Minga T; Solinsky C; Vargo DL; Winkelmayer WC
Am J Hematol; 2022 Sep; 97(9):1178-1188. PubMed ID: 35751858
[TBL] [Abstract][Full Text] [Related]
3. Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease.
Martin ER; Smith MT; Maroni BJ; Zuraw QC; deGoma EM
Am J Nephrol; 2017; 45(5):380-388. PubMed ID: 28343225
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD).
Noonan ML; Clinkenbeard EL; Ni P; Swallow EA; Tippen SP; Agoro R; Allen MR; White KE
Physiol Rep; 2020 Jun; 8(11):e14434. PubMed ID: 32476270
[TBL] [Abstract][Full Text] [Related]
5. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease.
Pergola PE; Spinowitz BS; Hartman CS; Maroni BJ; Haase VH
Kidney Int; 2016 Nov; 90(5):1115-1122. PubMed ID: 27650732
[TBL] [Abstract][Full Text] [Related]
6. Novel roles of HIF-PHIs in chronic kidney disease: the link between iron metabolism, kidney function, and FGF23.
Ikeda Y
Kidney Int; 2021 Jul; 100(1):14-16. PubMed ID: 34154707
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Characterization of Vadadustat (AKB-6548), an Oral Small Molecule Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, for the Potential Treatment of Renal Anemia.
Zuk A; Si Z; Loi S; Bommegowda S; Hoivik D; Danthi S; Molnar G; Csizmadia V; Rabinowitz M
J Pharmacol Exp Ther; 2022 Oct; 383(1):11-24. PubMed ID: 35926869
[TBL] [Abstract][Full Text] [Related]
8. The HIF-PHI BAY 85-3934 (Molidustat) Improves Anemia and Is Associated With Reduced Levels of Circulating FGF23 in a CKD Mouse Model.
Noonan ML; Ni P; Agoro R; Sacks SA; Swallow EA; Wheeler JA; Clinkenbeard EL; Capitano ML; Prideaux M; Atkins GJ; Thompson WR; Allen MR; Broxmeyer HE; White KE
J Bone Miner Res; 2021 Jun; 36(6):1117-1130. PubMed ID: 33592127
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: Design and baseline characteristics.
Chertow GM; Pergola PE; Agarwal R; Block GA; Farag YMK; Jardine AG; Koury MJ; Luo W; Khawaja Z; Lewis EF; Matsushita K; McCullough PA; Parfrey PS; Wittes J; Walters KA; Tseng C; Lin T; Sarnak MJ; Vargo DL; Winkelmayer WC; Eckardt KU
Am Heart J; 2021 May; 235():1-11. PubMed ID: 33129989
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis.
Eckardt KU; Agarwal R; Aswad A; Awad A; Block GA; Bacci MR; Farag YMK; Fishbane S; Hubert H; Jardine A; Khawaja Z; Koury MJ; Maroni BJ; Matsushita K; McCullough PA; Lewis EF; Luo W; Parfrey PS; Pergola P; Sarnak MJ; Spinowitz B; Tumlin J; Vargo DL; Walters KA; Winkelmayer WC; Wittes J; Zwiech R; Chertow GM
N Engl J Med; 2021 Apr; 384(17):1601-1612. PubMed ID: 33913638
[TBL] [Abstract][Full Text] [Related]
11. Factors affecting responsiveness of vadadustat in patients with anemia associated with chronic kidney disease: a post-hoc subgroup analysis of Japanese phase 3 randomized studies.
Nangaku M; Ueta K; Nishimura K; Sasaki K; Hashimoto T
Clin Exp Nephrol; 2024 May; 28(5):391-403. PubMed ID: 38530490
[TBL] [Abstract][Full Text] [Related]
12. Associations among erythropoietic, iron-related, and FGF23 parameters in pediatric kidney transplant recipients.
Limm-Chan B; Wesseling-Perry K; Pearl MH; Jung G; Tsai-Chambers E; Weng PL; Hanudel MR
Pediatr Nephrol; 2021 Oct; 36(10):3241-3249. PubMed ID: 33903951
[TBL] [Abstract][Full Text] [Related]
13. Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD.
Chertow GM; Pergola PE; Farag YMK; Agarwal R; Arnold S; Bako G; Block GA; Burke S; Castillo FP; Jardine AG; Khawaja Z; Koury MJ; Lewis EF; Lin T; Luo W; Maroni BJ; Matsushita K; McCullough PA; Parfrey PS; Roy-Chaudhury P; Sarnak MJ; Sharma A; Spinowitz B; Tseng C; Tumlin J; Vargo DL; Walters KA; Winkelmayer WC; Wittes J; Eckardt KU;
N Engl J Med; 2021 Apr; 384(17):1589-1600. PubMed ID: 33913637
[TBL] [Abstract][Full Text] [Related]
14. Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open-label study in Japan.
Nangaku M; Kondo K; Takabe S; Ueta K; Kaneko G; Otsuka M; Kawaguchi Y; Komatsu Y
Ther Apher Dial; 2021 Oct; 25(5):642-653. PubMed ID: 33283981
[TBL] [Abstract][Full Text] [Related]
15. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
[TBL] [Abstract][Full Text] [Related]
16. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
[TBL] [Abstract][Full Text] [Related]
17. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials.
Eckardt KU; Agarwal R; Farag YM; Jardine AG; Khawaja Z; Koury MJ; Luo W; Matsushita K; McCullough PA; Parfrey P; Ross G; Sarnak MJ; Vargo D; Winkelmayer WC; Chertow GM
Nephrol Dial Transplant; 2021 Nov; 36(11):2039-2048. PubMed ID: 33188693
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience.
Sanghani NS; Haase VH
Adv Chronic Kidney Dis; 2019 Jul; 26(4):253-266. PubMed ID: 31477256
[TBL] [Abstract][Full Text] [Related]
19. A phase 3, open-label, single-arm study of vadadustat for anemia in chronic kidney disease for Japanese patients on hemodialysis not receiving erythropoiesis-stimulating agents.
Nangaku M; Kondo K; Takabe S; Ueta K; Tandai T; Kawaguchi Y; Komatsu Y
Ther Apher Dial; 2022 Feb; 26(1):45-54. PubMed ID: 34115437
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.
Gupta N; Wish JB
Am J Kidney Dis; 2017 Jun; 69(6):815-826. PubMed ID: 28242135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
